Premium
Unfolding the pleiotropic facades of rosuvastatin in therapeutic intervention of myriads of neurodegenerative disorders
Author(s) -
Husain Ibraheem,
Khan Sana,
Khan Saba,
Madaan Tushar,
Kumar Sanjeev,
Najmi Abul K.
Publication year - 2019
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/1440-1681.13040
Subject(s) - rosuvastatin , neuroprotection , medicine , hmg coa reductase , neuroinflammation , rosuvastatin calcium , pharmacology , inflammation , oxidative stress , reductase , biology , enzyme , biochemistry
Summary Rosuvastatin, a 3‐hydroxy‐3‐methylglutaryl‐coenzyme ( HMG ‐CoA) reductase inhibitor, and one of the most popular antihyperlipidemic medications have been found to possess pharmacodynamic activities much different from its usual indication. Recent research studies have revealed the efficacy of rosuvastatin in attenuating neuroinflammation, reducing the progression of Alzheimer's disease, providing protection against cerebral ischaemia and spinal cord injury as well as ameliorating epilepsy. Mechanisms behind the neuroprotective potential of rosuvastatin can be attributed to its pleiotropic effects, independent of its ability to inhibit HMG ‐CoA reductase. These processes include modulation of several cellular pathways, isoprenylation, effects on oxidative stress, nitrosative levels, inflammation, and immune response. This review aims to assimilate and summarize recent findings on the pharmacological actions of rosuvastatin in attenuating neurological disorders in order to guide future research in this space.